TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23881862
Drug: Inappropriate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate therapy in diabetic patients
Study: 23881862
Drug: Appropriate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate therapy in diabetic patients
Study: 20827448
Drug: IR‐A irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR‐A irradiation treatment
Study: 18005966
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C and E supplementation (343 mg and 84 mg respectively)
Study: 16012275
Drug: Quetiapine dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine dosage escalation to 400 mg/d in 5 days
Study: 16012275
Drug: Quetiapine dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine dosage escalation to 400 mg/d in 3 days
Study: 16012275
Drug: Quetiapine dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine dosage escalation to 400 mg/d in 2 days
Study: 9892331
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (500 mg twice daily)
Study: 9892331
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin (200 mg twice daily)
Study: 29433500
Drug: Local neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local neck treatment
Study: 29433500
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment plus tailored sensorimotor exercises
Study: 29433500
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment plus balance exercises
Study: 29433500
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment plus sensorimotor and balance exercises
Study: 20647478
Drug: Neratinib (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (240 mg)
Study: 20647478
Drug: Neratinib (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (240 mg) plus ketoconazole
Study: 17582439
Drug: Intraspinal injections
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraspinal injections of autologous mesenchymal stem cells (MSCs) at the thoracic level
Study: 17582439
Drug: Intraspinal injections
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraspinal injections of autologous mesenchymal stem cells (MSCs)
Study: 11917904
Drug: Dihydrotestosterone (DHT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone (DHT; 70 mg/day) for 3 months
Study: 11917904
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for 3 months
Study: 7614103
Drug: Cisapride 30
Normalized name: cisapride 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 30 mg daily
Study: 1978771
Drug: Clindamycin, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin, 600 mg intravenously every 6 hours, followed by oral clindamycin, 300 mg every 6 hours for a minimum of 4 weeks.
Study: 1978771
Drug: Penicillin G,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin G, 2 million U every 4 hours for no less than 8 days, followed by oral penicillin V, 750 mg every 6 hours for a minimum of 4 weeks.
Study: 31116996
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) + photodynamic therapy (PDT)
Study: 28975543
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and B vaccine injection (accelerated schedule)
Study: 28975543
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B recombinant DNA vaccine (conventional schedule)
Study: 25880756
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 1200 mg QD
Study: 25880756
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 1600 mg QD
Study: 23718748
Drug: Insulin (n=32)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (n=32)
Study: 21262871
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg/day for 6 months
Study: 18937965
Drug: Oral irreversible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irreversible P2Y12 receptor antagonists
Study: 18937965
Drug: Reversible P2Y12
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversible P2Y12 receptor antagonists
Study: 15525860
Drug: Watchful Waiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watchful Waiting Intervention (WWI) - 5 weekly intervention calls from a nurse
Study: 2752179
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous gamma-globulin (400 mg/kg on days 1 through 5)
Study: 2752179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral prednisone and high-dose intravenous gamma-globulin
Study: 165913
Drug: ethinyl oestradiol
Normalized name: 17-ethinyl-3,17-oestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl oestradiol 20 mug daily
Study: 165913
Drug: ethinyl oestradiol
Normalized name: 17-ethinyl-3,17-oestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl oestradiol 50 mug daily
Study: 165913
Drug: conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conjugated equine oestrogens (Premarin) 0.625 mg daily
Study: 165913
Drug: conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conjugated equine oestrogens (Premarin) 1.25 mg daily
Study: 26149210
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL articaine (4% with 1:100,000 epinephrine)
Study: 26149210
Drug: 3.6 mL
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mL articaine (4% with 1:100,000 epinephrine)
Study: 22453111
Drug: Repeat onabotulinum
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat onabotulinum toxin A injections (both doses)
Study: 19207293
Drug: sTfR levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sTfR levels (3.50 +/- 0.07 mg/l)
Study: 7489418
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plain bupivacaine with buprenorphine
Study: 6283800
Drug: Fibre rich
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre rich breakfast (whole grain bread and whole apples, 8.4 g dietary fibre)
Study: 6283800
Drug: Fibre poor
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre poor breakfast (white bread and apple juice, 3.1 g dietary fibre)
Study: 23134880
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements and usual diet (group 2)
Study: 20155838
Drug: Combination antibiotics
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antibiotics (doxycycline and rifampin)
Study: 20155838
Drug: Combination antibiotics
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antibiotics
Study: 12768894
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 4% sodium chondroitin sulfate and 3% sodium hyaluronate
Study: 10172394
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural block with 1.2 mL/kg of 0.25% bupivacaine
Study: 2025147
Drug: Low-intensity treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity treatment (self-help booklet and 20-30 minute session with a trained counselor)
Study: 2025147
Drug: High-intensity treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity treatment (low-level treatments plus individually tailored follow-up treatments)
Study: 7469210
Drug: Minocycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline, 100 mg once or twice daily for 7 or 21 days
Study: 30904540
Drug: Intrastromal voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrastromal voriconazole (ISV) injection
Study: 30904540
Drug: Topical natamycin
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical natamycin alone
Study: 22226309
Drug: Homeopathy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathy treatment (individualized homeopathic medicines in fifty millesimal (LM) potencies)
Study: 22226309
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (including analgesics, antipyretics, and anti-inflammatory drugs)
Study: 12860733
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with methotrexate (MTX) and sulfasalazine (SSZ) during the first year
Study: 12860733
Drug: Single disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single disease modifying antirheumatic drug treatment
Study: 1588147
Drug: PRP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP vaccine
Study: 24612546
Drug: AST1306 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST1306 at 1000 mg BID
Study: 24612546
Drug: AST1306 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST1306 at 1500 mg BID
Study: 24612546
Drug: AST1306 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST1306 at 800 mg TID
Study: 24612546
Drug: AST1306 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST1306 at 1200 mg TID
Study: 24612546
Drug: AST1306 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST1306 (various doses)
Study: 19880790
Drug: rhIGF-I (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-I (40, 80, or 120 microg/kg, administered sc, twice daily)
Study: 19880790
Drug: rhIGF-I treatment
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF-I treatment
Study: 15604947
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of fractional change during treatment
Study: 12020483
Drug: PTMR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTMR plus maximal medical therapy (MMT)
Study: 9665202
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN) maintenance treatment at a starting dose of 3 mU/m2 three times per week.
Study: 9665202
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN) maintenance treatment.
Study: 9665202
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN) maintenance treatment and No treatment (control group).
Study: 2681410
Drug: Felodipine conventional
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine conventional (5 mg twice a day)
Study: 2681410
Drug: Felodipine extended
Normalized name: Felodipine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine extended release (10 mg once daily)
Study: 4479277
Drug: High-volume feeds
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume feeds (230 ml/kg/day of S.M.A. S26 milk)
Study: 4479277
Drug: Conventional feeds
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional feeds (180 ml/kg/day of S.M.A. S26 milk)
Study: 31860387
Drug: PQQ (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PQQ (20 mg/day)
Study: 26790796
Drug: Periarticular mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular mixture of drugs (bupivacaine, ketorolac, morphine, adrenaline)
Study: 17245476
Drug: Thiazolidinedione (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinedione (e.g., pioglitazone)
Study: 14512874
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) monotherapy
Study: 14512874
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFN-alpha) monotherapy
Study: 10436945
Drug: Nilestrioli 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilestrioli 2 mg twice a month and Perphenazine 12 mg and Doxepin 75 mg per day
Study: 10436945
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid 300 mg a day
Study: 2956874
Drug: Oral enoximone
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enoximone (150 mg 3 times daily)
Study: 2956874
Drug: Intravenous enoximone
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoximone (0.75 mg/kg)
Study: 31396995
Drug: PBK-1701TC (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBK-1701TC (320 mg simethicone)
Study: 28743135
Drug: Microsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical treatment
Study: 26418341
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg twice-daily plus Vitamin D3 1,000 IU twice-daily
Study: 21669891
Drug: Specialized care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized care group with brief physician training and computer-assisted medication management
Study: 15312348
Drug: Vp‐16 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vp‐16 1000 mg/m(2) with rhG‐CSF 300 microg.body(‐1).day(‐1)
Study: 15312348
Drug: Vp‐16 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vp‐16 1500 mg/m(2) with rhG‐CSF 300 microg.body(‐1).day(‐1)
Study: 15312348
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as the comparison group receiving different Vp‐16 dosage)
Study: 15994253
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebulised salbutamol
Study: 11514693
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salbutamol and ipratropium
Study: 9297994
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine 10-40 mg daily, possibly with enalapril 5-20 mg daily and hydrochlorothiazide 12.5-25.0 mg daily)
Study: 3556957
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg every 6 h intravenously and colloidal aluminium phosphate 11 g every 4 h per os
Study: 3556957
Drug: No preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preventive treatment
Study: 30322408
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients who never achieved drug-free status)
Study: 26420761
Drug: Standard anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anaesthetic treatment (Control)
Study: 25192393
Drug: Argentine tango
Normalized name: Argentine canola pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argentine tango (AT) class, 1 hour twice weekly for 2 years
Study: 12848633
Drug: Omeprazole, 10
Normalized name: Omeprazole, 10 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 10 or 20 mg once daily for 4 weeks
Study: 10827369
Drug: Lotrafiban (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafiban (up to 50 mg twice daily)
Study: 10827369
Drug: Aspirin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (standard therapy)
Study: 8890722
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no thyroxine administration)
Study: 8448808
Drug: Ioxaglate (ionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate (ionic contrast agent)
Study: 8448808
Drug: Iohexol (nonionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (nonionic contrast agent)
Study: 8448808
Drug: Nonionic agent
Normalized name: LANOLIN DERIVATES,NONIONIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic agent (iohexol)
Study: 3519243
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 75 mg/day
Study: 3519243
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination tablet containing 5 mg amiloride and 50 mg hydrochlorothiazide (Moduretic)
Study: 3519243
Drug: Amiloride 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 15 mg/day added to hydrochlorothiazide
Study: 3519243
Drug: Amiloride reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride reduced to 7.5 mg/day using Moduretic
Study: 25566573
Drug: Topical suspension
Normalized name: Topical Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical suspension formulation of calcipotriene 0.005%‐betamethasone dipropionate 0.064%
Study: 25566573
Drug: Ointment formulation
Normalized name: mineral oil / petrolatum / phenylephrine hydrochloride Rectal Ointment [Formulation R Ointment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment formulation of calcipotriene 0.005%‐betamethasone dipropionate 0.064%
Study: 25566573
Drug: Topical suspension
Normalized name: Topical Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical suspension formulation
Study: 18702951
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 or 30 mg/d for 6 months)
Study: 18702951
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 or 750 mg/d for 6 months)
Study: 10584050
Drug: (15)NH(4)Cl (3.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: (15)NH(4)Cl (3.45 mg (15)N*kg(‐)(1)*d(‐)(1))
Study: 10584050
Drug: (15)NH(4)Cl (3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: (15)NH(4)Cl (3.9 mg (15)N*kg(‐)(1)*d(‐)(1))
Study: 1808500
Drug: Piracetam (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (9 g daily) in group I
Study: 1808500
Drug: Piracetam (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (2.4 g daily) in group II
Study: 16135859
Drug: Risperidone (1-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1-6 mg per day)
Study: 11840417
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy agents (gemcitabine, topotecan, liposomal doxorubicin, prolonged oral etoposide) with platinum
Study: 1378147
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg
Study: 3572208
Drug: Labetalol 400
Normalized name: labetalol 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 400 mg
Study: 8527263
Drug: Carvedilol 6.25
Normalized name: carvedilol 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 6.25 mg
Study: 7908256
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg
Study: 30832617
Drug: Olaparib combined
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib combined with temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) for 6 weeks, followed by Olaparib as a single agent for 4 weeks during the radiotherapy period.
Study: 29179649
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 100 million allo-hMSCs
Study: 29179649
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 200 million allo-hMSCs
Study: 23550906
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg UPA
Study: 23550906
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg UPA
Study: 23550906
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg UPA
Study: 15117982
Drug: Fulvestrant (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (250 mg, intramuscular injection, once monthly)
Study: 15117982
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg, orally, once daily)
Study: 15117982
Drug: Fulvestrant (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (250 mg, intramuscular injection, once monthly) in ER+/PgR+ subgroup
Study: 15117982
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg, orally, once daily) in ER+/PgR+ subgroup
Study: 11694699
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro before breakfast